Episode
CareDx’s Second Act with CEO John Hanna
- Podcast
- Mendelspod Podcast
- Published
- Feb 17, 2026
- Duration seconds
- 328
- Processing state
not_requested- Canonical source
- https://www.mendelspod.com/p/caredxs-second-act-with-ceo-john
Actions
POST https://stenobird.com/v1/public/podcasts/mendelspod-podcast-742570/episodes/caredx-s-second-act-with-ceo-john-hanna/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/mendelspod-podcast-742570/caredx-s-second-act-with-ceo-john-hanna.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
This is a free preview of a paid episode. To hear more, visit www.mendelspod.com CareDx is a company on the move. For years, they have been a bellwether in molecular diagnostics. Their early bet on gene expression testing in transplant medicine, their bruising fight over Medicare coverage, and their pivot into cell-free DNA monitoring have all reflected the growing pains of precision medicine itself. Now, under CEO John Hanna, the company looks less like a single-test diagnostics firm and more like a clinical ecosystem. Hanna brings an unusual vantage point. He began his career in health insurance before moving into molecular diagnostics—giving him insight into both innovation and reimbursement. That dual perspective shaped CareDx’s recent evolution: focus tightly on a defined clinical niche—transplantation—while expanding horizontally into the tools, software, and services that surround it. Today, CareDx operates across three segments: lab products (including high-resolution HLA typing kits using PCR, NGS, and nanopore), a growing software and patient solutions business, and its flagship genomics portfolio led by AlloSure, its donor-derived cell-free DNA assay. What distinguishes the company now is its “solution selling” approach—engaging transplant centers not just with a test, but with workflow software, quality reporting tools, specialty pharmacy, and EMR integration. “Our solution selling strategy is working,” he says today. At the scientific core remains the effort to replace invasive biopsies with molecular monitoring. AlloSure’s innovation—detecting donor-derived cell-free DNA without requiring donor genotyping—made routine blood-based rejection monitoring scalable. Yet adoption is not purely technical. “The biggest challenge with our space is building belief t…